CHMP recommends Fluenz Tetra for Influenza
AstraZeneca has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Fluenz Tetra, a nasally administered four-strain live attenuated influenza vaccine, for the prevention of seasonal Influenza in eligible children and adolescents 24 months to 17 years of age. The CHMP�s positive opinion on Fluenz Tetra will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Should the EC approve Fluenz Tetra, it will replace Fluenz from the 2014-2015 flu season onwards.
In the US, Fluenz Tetra is marketed by the MedImmune Specialty Care Division of AstraZeneca, under the trade name FluMist Quadrivalent (Influenza Vaccine Live, Intranasal). FluMist Quadrivalent was approved by the fDA on 29 February 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins